Berkeley Lights — Merger or Acquisition (December 2022)
17 slides from Berkeley Lights's merger presentation, Dec 21, 2022
Slide 1: Berkeley Lights to Acquire IsoPlexis
Berkeley Lights to Acquire IsoPlexis Investor Presentation December 21, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements in this communication regarding the proposed transaction between Berkeley Lights and IsoPlexis, the expected timetable for completing the transaction, benefits and synergies of the transaction, future opportunities for the combined company and products a
Slide 3: Presenters
3 Presenters Siddhartha Kadia, Ph.D. CEO, BERKELEY LIGHTS Sean Mackay CEO, ISOPLEXIS Mehul Joshi CFO, BERKELEY LIGHTS
Slide 4: A Transformational Combination
A Transformational Combination Most comprehensive technology portfolio to isolate, manipulate, and characterize live cells (Nasdaq: CELL) A FUNCTIONAL CELL BIOLOGY COMPANY LIVE CELL, FUNCTIONAL BIOLOGY DEEP PROFILING OF SINGLE CELLS The only single-cell platform enabling functional proteomics + 4 Ne
Slide 5: PhenomeX: The Functional Cell Biology Company
PhenomeX: The Functional Cell Biology Company WHAT WE DO Enable scientists to unlock the potential of cell biology for research and clinical applications HOW WE DO IT By providing a deeper analysis of cell function while preserving the live cells of interest WHY IT MATTERS Because understanding the
Slide 6: Transaction Summary
Transaction Summary 6 All-stock transaction valued at $57.8 million ISO shareholders will receive 0.612 shares of Berkeley Lights stock for each IsoPlexis share they hold BLI shareholders will own approximately 75.2% and ISO shareholders will own approximately 24.8% of PhenomeX Siddhartha Kadia, Ph.
Slide 7: IsoPlexis at a Glance
IsoPlexis at a Glance 7 Highly Multiplexed Proteomic Barcoding 2. Single-cell capture 3. Highly multiplexed proteomic detection 1. Sample loaded onto chip 30+ Proteins Per Cell Rapidly Growing Installed Base Installed Base (Total Instruments) ‘21 ‘22 Accelerating the fight against our toughest disea
Slide 8: Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan
Accelerates Progress Across Every Pillar of Berkeley Lights’ Strategic Plan 8 Building a world-class team Prioritizing R&D return on investment Delivering consistent commercial execution Led by Berkeley Lights’ experienced Board of Directors Enhances a proven management team highly experienced in co
Slide 9: Accelerates Progress Across Every Pillar of Berkeley Lights' Strategic Plan (continued)
9 Participating in a larger cell biology market with a wide range of tools and services through cross-selling opportunities to existing and new customers Enabling significant productivity through combined R&D, G&A and supply chain / manufacturing infrastructure Evaluating M&A opportunities that will
Slide 10: IsoPlexis Addresses Key Elements of Berkeley Lights' M&A Framework
IsoPlexis Addresses Key Elements of Berkeley Lights’ M&A Framework 10 Accelerate Profitable Growth Leverage Current Cost Structure Synergistic M&Aoptions that expand total addressable market Complementary technology tuck-ins that expands BLI offerings Expansion of service offerings to existing and n
Slide 11: PhenomeX: Investment Highlights
PhenomeX: Investment Highlights 11 Expanded and balanced product portfolio at different price points with a focus on recurring revenue Platform for further consolidation in high-growth, single-cell biology tools space Substantially expanded access to larger cell biology market, enhanced commercial s
Slide 12: Accelerated Development Path for Expanded and Balanced Product Portfolio
Combination with ISO facilitates entry into high-growth academic research segments Creates balanced product portfolio Lower ASP solutions affiliated with a variety of different customer segments Unlocks various new applications Expanding installed base Provides ability to further leverage existing c
Slide 13: Significantly Expanded Overall Customer Base
Significantly Expanded Overall Customer Base Meaningfully expands breadth of BLI’s customer base and cross-selling opportunities while enhancing relationship with key overlapping accounts 13 Berkeley Lights Customers IsoPlexis Customers Overlapping commercial channels and significant customer comple
Slide 14: Cost Synergies Will Increase Profitability and Accelerate Timeline to Breakeven
Cost Synergies Will Increase Profitability and Accelerate Timeline to Breakeven 14 ~$70Mcost synergies annualized by 2024 ~$150Min revenue, generating positive operating cash flow by 2024 General and Administrative Cost Synergies Marketing Resources and Sales Operations Complementary R&D Capabilitie
Slide 15: Investment Highlights
Investment Highlights 15 Expanded and balanced product portfolio at different price points with a focus on recurring revenue Platform for further consolidation in high-growth, single-cell biology tools space Substantially expanded access to larger cell biology market, enhanced commercial scale, and
Slide 16: A Functional Cell Biology Company
A FUNCTIONAL CELL BIOLOGY COMPANY
Slide 17: Q&A Session
G BERKELEY LIGHTS | 228 isoplexis Q&A Session
Berkeley Lights — Merger or Acquisition (December 2022) on 6ix